# US 2019/0290721 A1 · Combination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0290721 A1
- Document ID: US20190290721A1
- Status: Published application
- Kind: A1
- Application number: 16/201,703
- Filed: 2018-11-27
- Published: 2019-09-26
- Earliest claimed: 2015-11-06
- Assignees: Genesis Pharma SA
- Applicants: Genesis Pharma SA
- Inventors: George Vogiatzis
- Web page: https://patentgrep.com/patent/US20190290721A1

## CPC

- A61K 38/13: Cyclosporins
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61K 38/26: Glucagons
- A61P 5/40: Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- C07K 14/605: Glucagons
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a combination comprising at least two of the following: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist, for instance a combination comprising at least two of (i) exenatide, or a functional derivative or analogue thereof, or a pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue thereof, or a pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof. Said combinations are suitable for cardioprotection and for treating and/or preventing ischemia and/or reperfusion injury. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same.

## Claims

### Claim 1

A combination comprising an insulin modulator, wherein the insulin modulator is exenatide or a pharmaceutically acceptable salt thereof, and an aldosterone antagonist, wherein the aldosterone antagonist is potassium canrenoate.

### Claim at position 2

2-11. (canceled)

### Claim 12 (depends on 1)

A combination according to claim 1 which comprises at least one further active pharmaceutical ingredient (API) selected from a beta blocker, a renin-angiotensin inhibitor, a statin (HMG-CoA reductase inhibitor), an inhibitor of platelet activation or aggregation, a phosphodiesterase-3 inhibitor, a calcium sensitizer, an antioxidant and an anti-inflammatory agent.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a combination according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13 in a form suitable for parenteral administration.

### Claim 15

(canceled)

### Claim 16

A pharmaceutical product comprising an insulin modulator, wherein the insulin modulator is exenatide, or a pharmaceutically acceptable salt thereof; and an aldosterone antagonist, wherein the aldosterone antagonist is potassium canrenoate.

### Claim at position 8

17-33. (canceled)

### Claim 34

A method of treating and/or preventing one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof, the following components: an insulin modulator, wherein the insulin modulator is exenatide, or a pharmaceutically acceptable salt thereof; and an aldosterone potassium canrenoate.

### Claim at position 10

35-37. (canceled)

### Claim 38 (depends on 34)

The method according to claim 34 wherein the ischemia and/or reperfusion injury is ischemia and/or reperfusion injury of the brain, heart, lung, or kidney.

### Claim 39 (depends on 34)

The method according to claim 34 wherein the components are administered parenterally.

### Claim 40 (depends on 34)

The method according to claim 34 wherein the components are administered during reperfusion.

### Claim 41 (depends on 34)

The method according to claim 34 wherein the components are administered before reperfusion.

### Claim 42 (depends on 34)

The method according to claim 34 wherein the components are administered after reperfusion.

### Claim 43 (depends on 34)

The method according to claim 34 which comprises simultaneously administering the components to said subject.

### Claim at position 17

44-61. (canceled)

### Claim 62 (depends on 13)

The pharmaceutical composition according to claim 13 in a form suitable for intravenous administration

### Claim 63 (depends on 16)

The pharmaceutical product according to claim 16, wherein the components are formulated for simultaneous administration.

### Claim 64 (depends on 16)

The pharmaceutical product according to claim 16, wherein the components are formulated for sequential administration.

### Claim 65 (depends on 16)

The pharmaceutical product according to claim 16, wherein the components are formulated for separate administration.

### Claim 66 (depends on 34)

The method according to claim 34, wherein the ischemia is myocardial ischemia.

### Claim 67 (depends on 34)

The method according to claim 34, wherein the reperfusion injury is myocardial reperfusion injury or acute myocardial infarction.

### Claim 68 (depends on 34)

The method according to claim 34, wherein the components are administered intravenously.

### Claim 69

A pharmaceutical product comprising an insulin modulator, wherein the insulin modulator is exenatide, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof; and an aldosterone antagonist, wherein the aldosterone antagonist is potassium canrenoate, or a functional derivative or analogue thereof.

### Claim 70 (depends on 69)

The pharmaceutical product according to claim 69, wherein the exenatide functional derivative or analogue is selected from lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265).

### Claim 71 (depends on 69)

A method of treating and/or preventing one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof; a pharmaceutical product of claim 69.
